Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.
- Published In:
- Headache, 58 Suppl 3, 276-290 (2018)
- Authors:
- Tepper, Stewart J(2)
- Database ID:
- RPEP-03942
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-03942APA
Tepper, Stewart J. (2018). Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.. Headache, 58 Suppl 3, 276-290. https://doi.org/10.1111/head.13417
MLA
Tepper, Stewart J. "Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Update on a Previous Review After the American Headache Society 60th Scientific Meeting, San Francisco, June 2018.." Headache, 2018. https://doi.org/10.1111/head.13417
RethinkPeptides
RethinkPeptides Research Database. "Anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: Updat..." RPEP-03942. Retrieved from https://rethinkpeptides.com/research/tepper-2018-anticalcitonin-generelated-peptide-cgrp
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.